CEO's message


The world’s best nanomedicine pharmaceutical company

Seung-Hoon Lee, MD, PhD, FAHA

In the winter of 2011, when iron oxide nanoparticles as MRI contrast agents were not as successful as they were spotlighted, our team came across cerium oxide nanoparticles.

A year later, we published a study in Angewandte Chemie, one of the leading chemistry journals, demonstrating the therapeutic effects of this material on acute ischemic stroke models.

Not only has the potency and biocompatibility of the product improved through earnest and passionate research, but further research has enabled us to prove the effects of cerium oxide nanoparticles against serious inflammatory diseases, acute intracerebral hemorrhage, sepsis, and subarachnoid hemorrhage.


Our study on subarachnoid hemorrhage model was recognized for academic excellence and it received the Basic Science award at the International Stroke Conference held by the American Stroke Association in February 2018. By reporting the effects of cerium oxide nanoparticles on every stroke subtype, Cenyx has become a global expert in the field of clinical application of inorganic nanoparticles.

These nanoparticles have recently been named “nanozyme” as they mimic the function of intrinsic enzymes with magnified potency due to their huge surface-to-volume ratio.

Few companies have focused on clinical applications of nanozymes, although this area of research has been highlighted for more than a decade in academia. Cenyx is the first nanozyme biotech company founded by an experienced research team from a university hospital in Korea.​ Although nanozymes have not yet been developed in the conventional pharmaceutical industry, they would have immeasurable social and economic implications once proven as applicable in humans because of their therapeutic potential.

How many people could predict monoclonal antibody technology would be the most important therapeutic in the global pharmaceutical and healthcare industries in the 1990s when only a few biologics had been commercialized?​ The field of nanocatalytic medicine has just begun to develop. Starting as a small biotech startup, Cenyx biotech is constantly striving for clinical application of nanozymes. The goal of our team is to translate the potential of nanozymes into medicines and make Cenyx the world’s best nanomedicine pharmaceutical company in 10 years. We will constantly improve our efforts to provide new solutions for people living with serious diseases around the world.

Seung-Hoon Lee, MD, PhD, FAHA
CEO, Cenyx Biotech Inc.